The Street isn't giving much (if any) value to the pipeline. The $15/share price is reflective of only the 393M on hand cash which decreases on a monthly basis with the expected burn rate. With the sale of the royalties, the amount coming in from Abbvie isn't replacing and/or adding to the cash on hand. In summary, with each passing month, the on hand cash decreases and the stock price goes along with it. Correct me if I am wrong....?
News 
Market Data 
Discover 
AI
